Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Injuries | 11 | 2023 | 2057 | 1.530 |
Why?
|
Brain Concussion | 7 | 2024 | 1435 | 1.330 |
Why?
|
Decompressive Craniectomy | 3 | 2022 | 76 | 1.110 |
Why?
|
Football | 3 | 2024 | 506 | 0.870 |
Why?
|
Mannitol | 2 | 2022 | 176 | 0.840 |
Why?
|
Cerebrovascular Trauma | 1 | 2022 | 21 | 0.820 |
Why?
|
Vasospasm, Intracranial | 3 | 2021 | 207 | 0.770 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2022 | 111 | 0.730 |
Why?
|
Coma | 2 | 2021 | 485 | 0.730 |
Why?
|
Hematoma, Subdural | 1 | 2021 | 128 | 0.710 |
Why?
|
Diffuse Axonal Injury | 2 | 2017 | 49 | 0.700 |
Why?
|
Diuretics, Osmotic | 1 | 2019 | 32 | 0.680 |
Why?
|
Saline Solution, Hypertonic | 1 | 2019 | 115 | 0.650 |
Why?
|
Vascular System Injuries | 1 | 2022 | 248 | 0.640 |
Why?
|
Moyamoya Disease | 2 | 2021 | 274 | 0.620 |
Why?
|
Brain Stem Hemorrhage, Traumatic | 1 | 2017 | 13 | 0.590 |
Why?
|
Tauopathies | 1 | 2021 | 328 | 0.550 |
Why?
|
Spinal Cord Injuries | 1 | 2024 | 928 | 0.520 |
Why?
|
Edema | 2 | 2020 | 765 | 0.490 |
Why?
|
Intracranial Hemorrhages | 4 | 2024 | 810 | 0.480 |
Why?
|
Electric Injuries | 1 | 2014 | 24 | 0.480 |
Why?
|
Injury Severity Score | 4 | 2023 | 1049 | 0.400 |
Why?
|
Neurology | 2 | 2018 | 786 | 0.400 |
Why?
|
Brain Stem | 1 | 2017 | 859 | 0.400 |
Why?
|
Lung Diseases | 1 | 2022 | 1944 | 0.380 |
Why?
|
Optic Nerve Diseases | 1 | 2014 | 342 | 0.360 |
Why?
|
Cerebral Hemorrhage | 2 | 2020 | 2655 | 0.350 |
Why?
|
tau Proteins | 1 | 2021 | 2144 | 0.340 |
Why?
|
Status Epilepticus | 3 | 2023 | 463 | 0.340 |
Why?
|
Encephalitis, Herpes Simplex | 2 | 2023 | 65 | 0.330 |
Why?
|
Methylprednisolone | 3 | 2024 | 386 | 0.330 |
Why?
|
Chronic Disease | 2 | 2022 | 9384 | 0.330 |
Why?
|
Withholding Treatment | 1 | 2013 | 620 | 0.320 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1883 | 0.310 |
Why?
|
Brain Ischemia | 2 | 2021 | 3007 | 0.310 |
Why?
|
Corpus Callosum | 3 | 2019 | 753 | 0.300 |
Why?
|
Stroke | 3 | 2020 | 9755 | 0.290 |
Why?
|
Critical Care | 2 | 2018 | 2715 | 0.290 |
Why?
|
Heart-Assist Devices | 1 | 2018 | 1292 | 0.280 |
Why?
|
Brain | 5 | 2021 | 27360 | 0.280 |
Why?
|
Dementia | 1 | 2021 | 2740 | 0.270 |
Why?
|
Hypertension | 2 | 2024 | 8616 | 0.250 |
Why?
|
Mental Disorders | 2 | 2022 | 6874 | 0.240 |
Why?
|
Comorbidity | 3 | 2024 | 10590 | 0.220 |
Why?
|
Curriculum | 1 | 2017 | 3782 | 0.210 |
Why?
|
Intensive Care Units | 3 | 2021 | 3800 | 0.210 |
Why?
|
Humans | 55 | 2024 | 768166 | 0.210 |
Why?
|
Subarachnoid Hemorrhage | 3 | 2021 | 1024 | 0.200 |
Why?
|
Anterior Temporal Lobectomy | 2 | 2023 | 46 | 0.190 |
Why?
|
Middle Aged | 27 | 2024 | 223492 | 0.180 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15948 | 0.180 |
Why?
|
Muscle Weakness | 2 | 2015 | 412 | 0.180 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15662 | 0.180 |
Why?
|
Electrolytes | 1 | 2022 | 279 | 0.180 |
Why?
|
Mannose-Binding Lectin | 1 | 2022 | 146 | 0.180 |
Why?
|
Prognosis | 6 | 2023 | 30010 | 0.170 |
Why?
|
Cerebral Hemorrhage, Traumatic | 1 | 2019 | 20 | 0.170 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2020 | 146 | 0.160 |
Why?
|
Intracranial Thrombosis | 1 | 2020 | 109 | 0.160 |
Why?
|
Retrospective Studies | 13 | 2024 | 81762 | 0.160 |
Why?
|
Inflammation | 4 | 2020 | 10873 | 0.160 |
Why?
|
Drainage | 2 | 2023 | 1183 | 0.160 |
Why?
|
Male | 34 | 2024 | 364719 | 0.160 |
Why?
|
Cerebral Revascularization | 1 | 2021 | 260 | 0.160 |
Why?
|
Adult | 24 | 2024 | 223646 | 0.150 |
Why?
|
Cerebrospinal Fluid | 1 | 2021 | 540 | 0.150 |
Why?
|
Amnesia | 1 | 2019 | 257 | 0.140 |
Why?
|
Hippocampus | 2 | 2021 | 3785 | 0.140 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 260 | 0.140 |
Why?
|
Adolescent | 11 | 2024 | 89169 | 0.140 |
Why?
|
Head Injuries, Penetrating | 1 | 2016 | 28 | 0.140 |
Why?
|
Health Occupations | 1 | 2018 | 225 | 0.130 |
Why?
|
Aged | 18 | 2024 | 171504 | 0.130 |
Why?
|
Internship and Residency | 1 | 2017 | 5953 | 0.130 |
Why?
|
Necrosis | 1 | 2020 | 1616 | 0.130 |
Why?
|
International Normalized Ratio | 1 | 2018 | 382 | 0.130 |
Why?
|
Quality of Life | 3 | 2024 | 13490 | 0.130 |
Why?
|
Athletic Injuries | 2 | 2024 | 1245 | 0.130 |
Why?
|
Anticoagulants | 2 | 2024 | 4852 | 0.130 |
Why?
|
Glasgow Coma Scale | 4 | 2019 | 574 | 0.130 |
Why?
|
Female | 28 | 2024 | 397192 | 0.120 |
Why?
|
Heart Valve Prosthesis | 1 | 2024 | 1468 | 0.120 |
Why?
|
Diffusion Tensor Imaging | 2 | 2016 | 2420 | 0.120 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 9263 | 0.120 |
Why?
|
Dantrolene | 1 | 2014 | 26 | 0.120 |
Why?
|
Synapses | 1 | 2024 | 1765 | 0.120 |
Why?
|
Glasgow Outcome Scale | 1 | 2014 | 101 | 0.120 |
Why?
|
Brain Waves | 1 | 2018 | 417 | 0.120 |
Why?
|
Paresis | 1 | 2015 | 177 | 0.120 |
Why?
|
Hydrocephalus | 1 | 2021 | 768 | 0.110 |
Why?
|
Blood-Brain Barrier | 1 | 2020 | 1034 | 0.110 |
Why?
|
Muscle Relaxants, Central | 1 | 2014 | 93 | 0.110 |
Why?
|
Aphasia | 1 | 2015 | 193 | 0.110 |
Why?
|
Heart Failure | 1 | 2018 | 11879 | 0.110 |
Why?
|
Protein Kinases | 1 | 2020 | 1611 | 0.110 |
Why?
|
Leukoaraiosis | 1 | 2014 | 114 | 0.110 |
Why?
|
Young Adult | 10 | 2024 | 60066 | 0.100 |
Why?
|
Cerebral Angiography | 1 | 2018 | 1264 | 0.100 |
Why?
|
Olivary Nucleus | 1 | 2013 | 131 | 0.100 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14783 | 0.100 |
Why?
|
Microglia | 2 | 2018 | 1376 | 0.100 |
Why?
|
Cerebrovascular Circulation | 1 | 2022 | 2725 | 0.100 |
Why?
|
Prospective Studies | 6 | 2024 | 54926 | 0.100 |
Why?
|
Intracranial Aneurysm | 1 | 2021 | 1271 | 0.090 |
Why?
|
Anesthesia, General | 1 | 2018 | 1189 | 0.090 |
Why?
|
Neuroprotective Agents | 2 | 2014 | 958 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1323 | 0.090 |
Why?
|
Hypnotics and Sedatives | 1 | 2018 | 1191 | 0.090 |
Why?
|
Acute Disease | 2 | 2018 | 7243 | 0.090 |
Why?
|
Administration, Intranasal | 2 | 2023 | 485 | 0.090 |
Why?
|
Inpatients | 1 | 2022 | 2566 | 0.090 |
Why?
|
Organ Transplantation | 1 | 2020 | 1176 | 0.090 |
Why?
|
Pneumonia | 1 | 2021 | 2163 | 0.080 |
Why?
|
Ischemia | 1 | 2018 | 1900 | 0.080 |
Why?
|
Risk Factors | 6 | 2024 | 74944 | 0.080 |
Why?
|
Warfarin | 1 | 2018 | 1493 | 0.080 |
Why?
|
Muscular Atrophy, Spinal | 1 | 2012 | 260 | 0.080 |
Why?
|
Neurodegenerative Diseases | 1 | 2018 | 1095 | 0.080 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1512 | 0.080 |
Why?
|
Postoperative Complications | 2 | 2021 | 15832 | 0.080 |
Why?
|
Genomics | 1 | 2024 | 5926 | 0.080 |
Why?
|
Nervous System Diseases | 1 | 2019 | 1662 | 0.080 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12795 | 0.070 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39348 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4206 | 0.070 |
Why?
|
Incidence | 3 | 2024 | 21538 | 0.070 |
Why?
|
Registries | 2 | 2021 | 8375 | 0.070 |
Why?
|
Graft Rejection | 1 | 2020 | 4492 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18349 | 0.070 |
Why?
|
Aspirin | 1 | 2018 | 3135 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2014 | 1179 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 2763 | 0.060 |
Why?
|
Athletes | 2 | 2024 | 1162 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 13014 | 0.060 |
Why?
|
Mice | 6 | 2023 | 82029 | 0.060 |
Why?
|
Databases, Factual | 1 | 2021 | 8080 | 0.060 |
Why?
|
Cohort Studies | 4 | 2021 | 41754 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2013 | 928 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2020 | 5349 | 0.060 |
Why?
|
Animals | 9 | 2023 | 169246 | 0.060 |
Why?
|
Lymphoma | 1 | 2013 | 1898 | 0.060 |
Why?
|
Trauma Centers | 2 | 2019 | 951 | 0.050 |
Why?
|
Acyclovir | 1 | 2023 | 267 | 0.050 |
Why?
|
Osmolar Concentration | 1 | 2022 | 657 | 0.050 |
Why?
|
Water-Electrolyte Balance | 1 | 2022 | 326 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59629 | 0.050 |
Why?
|
rho-Associated Kinases | 1 | 2023 | 290 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2023 | 354 | 0.050 |
Why?
|
Milrinone | 1 | 2021 | 86 | 0.050 |
Why?
|
California | 1 | 2024 | 1438 | 0.040 |
Why?
|
Recovery of Function | 2 | 2021 | 2981 | 0.040 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2021 | 197 | 0.040 |
Why?
|
Massachusetts | 2 | 2024 | 8890 | 0.040 |
Why?
|
Cerebral Veins | 1 | 2020 | 157 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2023 | 638 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2021 | 3858 | 0.040 |
Why?
|
Cell Membrane Permeability | 1 | 2020 | 571 | 0.040 |
Why?
|
Consciousness Disorders | 1 | 2023 | 445 | 0.040 |
Why?
|
GTP-Binding Proteins | 1 | 2023 | 948 | 0.040 |
Why?
|
Hyperkinesis | 1 | 2018 | 88 | 0.040 |
Why?
|
Age Factors | 3 | 2021 | 18412 | 0.040 |
Why?
|
Hematoma | 1 | 2022 | 766 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36743 | 0.030 |
Why?
|
Interleukin-18 | 1 | 2018 | 251 | 0.030 |
Why?
|
Consciousness | 1 | 2022 | 602 | 0.030 |
Why?
|
Maze Learning | 1 | 2018 | 482 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2024 | 4860 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 1737 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
Arousal | 1 | 2021 | 1180 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2023 | 1815 | 0.030 |
Why?
|
Models, Immunological | 1 | 2017 | 518 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 863 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2022 | 1835 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 65371 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2020 | 14488 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1600 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1216 | 0.030 |
Why?
|
United States | 4 | 2024 | 73039 | 0.030 |
Why?
|
Patient Admission | 1 | 2020 | 1365 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2020 | 1862 | 0.030 |
Why?
|
Riluzole | 1 | 2012 | 62 | 0.030 |
Why?
|
Anisotropy | 1 | 2016 | 1292 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2023 | 22379 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2017 | 733 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2018 | 1027 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6082 | 0.020 |
Why?
|
Hypertrophy | 1 | 2013 | 562 | 0.020 |
Why?
|
Occupational Therapy | 1 | 2012 | 141 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2021 | 3228 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 696 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13586 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2018 | 1667 | 0.020 |
Why?
|
Time Factors | 2 | 2024 | 40218 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22371 | 0.020 |
Why?
|
Regression Analysis | 1 | 2019 | 6340 | 0.020 |
Why?
|
Vascular Diseases | 1 | 2018 | 1162 | 0.020 |
Why?
|
Seizures | 1 | 2023 | 2998 | 0.020 |
Why?
|
Arm | 1 | 2012 | 591 | 0.020 |
Why?
|
Astrocytes | 1 | 2017 | 1350 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1567 | 0.020 |
Why?
|
Physical Therapy Modalities | 1 | 2012 | 533 | 0.020 |
Why?
|
Medicaid | 1 | 2022 | 2840 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8509 | 0.020 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2014 | 558 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2013 | 1836 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3628 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8741 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2756 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15869 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2023 | 15454 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16726 | 0.020 |
Why?
|
Education, Medical | 1 | 2018 | 1742 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4427 | 0.020 |
Why?
|
HIV Infections | 1 | 2012 | 17569 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2023 | 7876 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5889 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10266 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2017 | 3080 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1805 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6809 | 0.010 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2012 | 1903 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10399 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10101 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3912 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3479 | 0.010 |
Why?
|
Viral Load | 1 | 2012 | 3396 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12077 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13671 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26379 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2020 | 4887 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10099 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 19015 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 24315 | 0.010 |
Why?
|
Clinical Competence | 1 | 2018 | 4858 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 20760 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13290 | 0.010 |
Why?
|
Neurons | 1 | 2020 | 9514 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10840 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2014 | 12465 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14164 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
Child, Preschool | 1 | 2016 | 42669 | 0.010 |
Why?
|
Concepts
(243)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(80)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_